Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD371-specific/YSNVz/IL-18 CAR T cells

A preparation of T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type lectin domain family 12 member A (CLEC12A, CCL1, CD371), and expressing the pro-inflammatory cytokine interleukin 18 (IL-18), with potential antineoplastic activity. Upon intravenous administration, CD371-specific/YSNVz/IL-18 CAR T cells target, bind to, and induce selective toxicity in CD371-expressing tumor cells. IL-18 promotes T-cell persistence and potentiates the immune response against tumor cells. CD371 is expressed on the surface of acute myeloid leukemia (AML) cells and leukemic stem cells, but it is not expressed on normal hematopoietic stem cells (HSCs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD371-YSNVz-IL-18 CAR T cells
CD371-specific/YSNVz/IL-18 CAR-T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search